# Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice

> **NCT06907082** · NA · COMPLETED · sponsor: **Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia** · enrollment: 106 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.

## Key facts

- **NCT ID:** NCT06907082
- **Lead sponsor:** Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907082, "Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06907082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*